Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $593000.0.

  • Exagen's Share-based Compensation rose 17327.19% to $593000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 989.01%. This contributed to the annual value of $1.8 million for FY2024, which is 5125.79% down from last year.
  • Per Exagen's latest filing, its Share-based Compensation stood at $593000.0 for Q3 2025, which was up 17327.19% from $443000.0 recorded in Q2 2025.
  • Exagen's 5-year Share-based Compensation high stood at $1.4 million for Q2 2022, and its period low was $217000.0 during Q3 2024.
  • Over the past 5 years, Exagen's median Share-based Compensation value was $890000.0 (recorded in 2023), while the average stood at $856052.6.
  • In the last 5 years, Exagen's Share-based Compensation tumbled by 7561.8% in 2024 and then skyrocketed by 17327.19% in 2025.
  • Quarter analysis of 5 years shows Exagen's Share-based Compensation stood at $1.2 million in 2021, then crashed by 50.55% to $582000.0 in 2022, then surged by 31.1% to $763000.0 in 2023, then tumbled by 43.25% to $433000.0 in 2024, then soared by 36.95% to $593000.0 in 2025.
  • Its Share-based Compensation was $593000.0 in Q3 2025, compared to $443000.0 in Q2 2025 and $417000.0 in Q1 2025.